engleski

An additional perspective on proton pump inhibitors as risk factors for COVID-19

We read with great interest a recent paper in Clinical Drug Investigation by Charpiat et al. entitled “Proton Pump Inhibitors are Risk Factors for Viral Infections: Even for COVID-19?” [1]. The authors discuss potential implications of the use of proton pump inhibitors (PPIs) amidst the COVID- 19 pandemic and suggest they should be used with caution as (i) alkalinisation of gastric acid removes the protective barrier towards ingested microorganisms ; (ii) PPI treatment has been proposed as a risk factor for some viral infections (rotavirus, influenza virus, norovirus, and Middle East respiratory syndrome coronavirus) ; and (iii) evidence of faecal- oral transmission has been reported for SARS-CoV-2. Considering the widespread use of PPIs and the serious situation regarding the ongoing COVID-19 pandemic, we recognise the manuscript by Charpiat et al. as highly relevant and wish to put forward an additional perspective that is pertinent to the discussion of PPIs as risk factors for COVID-19.

COVID-19 ; proton pump inhibitors

nije evidentirano